Using IL-6 levels to guide antibiotic use in COPD flare-ups
Part of Lungs & breathing clinical trials.
This trial tests whether a simple blood test for a marker called Interleukin-6 (IL-6) can help doctors decide when antibiotics are needed for patients hospitalized with a COPD flare-up (AECOPD). The goal is to reduce unnecessary antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are hospitalized for a COPD flare-up (worsening of symptoms).
- Your flare-up has lasted at least 24 hours, but no more than 21 days.
- You are between 40 and 80 years old.
- You have smoked at least 10 pack-years (e.g., 1 pack a day for 10 years).
- You have not taken antibiotics in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether treating a specific germ (Pneumocystis jirovecii) in the lungs can reduce the number of COPD flare-ups. If you have COPD with frequent flare-ups and this germ is found in your sputum, you may benefit.
This study looks at how common a certain type of white blood cell (eosinophil) is in people with COPD during a flare-up, and whether it affects how they do over time. It may help doctors learn if measuring eosinophils can guide treatment for COPD flare-ups.
This study tests a new treatment for people with COPD who still have frequent flare-ups despite using two maintenance inhalers. It aims to see if the study medicine can reduce these flare-ups.
This trial uses two simple blood tests (MxA and CRP) to help doctors decide whether you need antibiotics for a COPD flare-up. It aims to use medicines more wisely and avoid unnecessary side effects.
This study uses a simple blood test to help doctors decide if people having a COPD flare-up need antibiotics or steroids. It may help you get the right treatment faster and avoid unnecessary medications.
This trial checks whether using fast test results (PCR from samples, a blood marker called procalcitonin, and sputum appearance) can safely reduce how long you need antibiotics during a severe COPD flare. It may help you receive fewer days of antibiotics while still controlling the infection risk.
Hear when a new Chronic Obstructive Pulmonary Disease, COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.